Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Monday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS stock opened at $0.02 on Monday. The company’s 50-day simple moving average is $0.21 and its 200-day simple moving average is $0.49. Ayala Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $1.49. The firm has a market cap of $852,600.00, a P/E ratio of 0.00 and a beta of 1.55.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.